Achillion’s hep C drug remains in limbo 2Achillion Pharmaceuticals recently announced that the US Food and Drug Administration (FDA) has decided to maintain its clinical hold on sovaprevir, the company’s flagship treatment for hepatitis C.

The recent clinical data submitted by Achillion sought to address the issues previously flagged up by the FDA but the administration has decided that removal of the clinical hold is not warranted.

Milind Deshpande, chief exeuctive, said: “While we are disappointed that we were not able to resolve the clinical hold at this time despite having addressed all the issues, we believe the breadth of our portfolio allows to quickly advance other all oral combination regimens for the treatment of hepatitis C virus”.

Read more on our coverage of the story here:



Hepatitis C News

The team at works hard to deliver relevant and accessible information on hepatitis C, an infectious liver disease that affects around 150 million people worldwide. Updated daily, features topical news stories from around the world, tips and advice on living well with the hep C virus and guest blogs. Often referred to as a silent disease, as in most cases it does not result in any symptoms, hepatitis C is most commonly transmitted through contact with an infected person’s blood. The hepatitis C virus can cause serious damage to the liver and, if left untreated, can result in scarring of the liver, liver disease or even death.

Add a comment

Your email address will not be published. Required fields are marked *